Details of the Drug

General Information of Drug (ID: DMV7IM6)

Drug Name

Histamine Phosphate

Synonyms

Histamine acid phosphate; Histamine biphosphate; Histamine dihydrogen phosphate; Histamine diphosphate; Histamine phosphate [USP]; Histamine positive; H0147; Histamine phosphate (TN); Histamine phosphate (USP); Histamine phosphate (1:2); 1H-Imidazole-4-ethanamine, phosphate (1:2); 2-Imidazol-4-ylethylamine orthophosphoric acid (1:2); 4-(2-Aminoethyl)imidazole bis(dihydrogen phosphate); 4-(2-Aminoethyl)imidazole di-acid phosphate; 4-2(2-Aminoethyl)Imidazole-Di-Acid Phosphate

Indication

Disease Entry	ICD 11	Status	REF
Diagnostic imaging	N.A.	Approved	[1]

Therapeutic Class

Diagnostic Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski):
1

Molecular Weight

307.14

Topological Polar Surface Area

Not Available

Rotatable Bond Count

2

Hydrogen Bond Donor Count

8

Hydrogen Bond Acceptor Count

10

Chemical Identifiers

Formula: C5H15N3O8P2
IUPAC Name: 2-(1H-imidazol-5-yl)ethanamine;phosphoric acid
Canonical SMILES: C1=C(NC=N1)CCN.OP(=O)(O)O.OP(=O)(O)O
InChI: InChI=1S/C5H9N3.2H3O4P/c6-2-1-5-3-7-4-8-5;2*1-5(2,3)4/h3-4H,1-2,6H2,(H,7,8);2*(H3,1,2,3,4)
InChIKey: ZHIBQGJKHVBLJJ-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 65513
ChEBI ID: CHEBI:51193
CAS Number: 51-74-1
TTD ID: D0EN0G

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Histamine receptor (HR)	TT7CXIM	NOUNIPROTAC	Modulator	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 000734.
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
3	Mechanism of action of MY-1250, an active metabolite of Repirinast, in inhibiting histamine release from rat mast cells. Br J Pharmacol. 1992 Mar;105(3):587-90.
4	Oxidation of histamine H1 antagonist mequitazine is catalyzed by cytochrome P450 2D6 in human liver microsomes. J Pharmacol Exp Ther. 1998 Feb;284(2):437-42.
5	Clinical pipeline report, company report or official report of e-Therapeutics.
6	LCB 2183 inhibits the inflammation associated with oxazolone-induced contact sensitivity. Int J Immunopharmacol. 1994 Aug;16(8):675-83.
7	CA patent application no. 520580, Histamine binding compounds for treatment method for disease conditions mediated by neutrophils.
8	Clinical pipeline report, company report or official report of Orexo.
9	Effects of tesmilifene, a substrate of CYP3A and an inhibitor of P-glycoprotein, on the pharmacokinetics of intravenous and oral docetaxel in rats. J Pharm Pharmacol. 2010 Aug;62(8):1084-8.
10	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025139)
11	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016819)